672 www.thelancet.com/neurology Vol 10 August 2011 Since the fi nding that cholesterol-lowering statins could induce T-cell-mediated immune modulation and reverse paralysis in mice with experimental autoimmune encephalomyelitis (EAE), there has been substantial interest in whether this class of drugs is benefi cial in multiple sclerosis. One question that has not been answered is whether a stat...

multiple sclerosis (ms) is an inflammatory, multifocal, immune-mediated disease of the central nervous system that women are at a higher risk to acquire than men. myxovirus resistance protein a (mxa) is used as a predictive marker of bioactivity of interferon-beta (ifn-β) therapy in ms patients. this study was undertaken in west of iran to investigate gender differences in the expression level ...

BACKGROUND Interferon beta (IFNbeta) reduces relapses and MRI activity in relapsing-remitting MS (RRMS), with variable effects on disability. The most effective dose regimen remains controversial. METHODS This randomized, controlled, multicenter trial compared the efficacy and safety of IFNbeta-1a (Rebif) 44 micro g subcutaneously three times weekly (tiw), and IFNbeta-1a (Avonex) 30 micro g I...

Coexistence of multiple sclerosis (MS) with other autoimmune diseases has been attributed to common background genetic or environmental factors. This study presents development of rheumatoid arthritis (RA) during treatment of MS. The MS was confirmed by the Mc Donald criteria and the diagnosis of RA was confirmed by the ACR/EULAR criteria. A 35 years old women with 9 years of MS who was receivi...

Eleven male patients with genital warts were given injections of fibroblast interferon (300 u) and placebo into the bases of two similar warts. The changes in size of the treated warts compared with that of the controls suggested that interferon did inhibit the growth of the warts. The dose given was probably insufficient for a dramatic effect. In one patient, however, a wart on the penile shaf...

Interferon-beta 1a (IFNβ-1a) has been shown some promising effects on the management of severe COVID-19. We aimed to evaluate efficacy and safety IFNβ-1a in patients with confirmed mild moderate Respiratory rate (RR) saturation oxygen (SpO2) were considered as primary objectives study. This cross-sectional randomized controlled clinical trial was conducted for 6 months. All received acetaminoph...

INTRODUCTION 'No evidence of disease activity' (NEDA) is increasingly used as a treatment target with disease-modifying drugs for relapsing multiple sclerosis. METHODS This post-hoc analysis of the randomised EVIDENCE trial compared interferon beta-1a injected subcutaneously three times weekly (IFN β-1a SC tiw) with interferon β-1a injected intramuscularly once weekly (IFN β-1a IM qw) on NEDA...